罗马III与罗马IV标准肠易激综合征患者中乳糜泻的全球患病率:系统综述与荟萃分析
该系统综述与荟萃分析检索至2025年1月,纳入29项研究共7209例肠易激综合征患者,评估乳糜泻患病率。肠易激综合征患者乳糜泻血清学阳性合并患病率为6%(95%CI 5%-8%),活检确诊患病率为2%(95%CI 2%-3%),血清学阳性者中15%(95%CI 6%-24%)未行内镜和活检。肠易激综合征患者血清学阳性比值比显著高于对照(OR 4.42;95%CI 2.82-6.92)。
要点
- 肠易激综合征患者乳糜泻血清学阳性合并患病率为6%(95%CI 5%-8%)。
- 活检确诊乳糜泻合并患病率为2%(95%CI 2%-3%)。
- 肠易激综合征患者血清学阳性比值比显著高于对照(OR 4.42;95%CI 2.82-6.92)。
核心结论
- 在符合罗马III和罗马IV标准的肠易激综合征患者中,乳糜泻患病率较高。
- 作者认为,不排除乳糜泻不应作出肠易激综合征的阳性诊断。
研究设计与样本
- 系统综述与荟萃分析,检索多个数据库至2025年1月。
- 纳入29项研究,共7209例肠易激综合征患者。
- 纳入研究使用罗马III或罗马IV标准诊断肠易激综合征,采用组织转谷氨酰胺酶、肌内膜抗体或脱酰胺麦胶蛋白肽血清学筛查和/或十二指肠活检确诊乳糜泻。
- 采用随机效应荟萃分析估计合并患病率及95%CI,计算合并比值比比较肠易激综合征患者与对照的乳糜泻可能性。
主要发现
- 肠易激综合征患者乳糜泻血清学阳性合并患病率为6%(95%CI 5%-8%)。
- 活检确诊乳糜泻合并患病率为2%(95%CI 2%-3%)。
- 血清学阳性患者中15%(95%CI 6%-24%)未行内镜和活检。
- 肠易激综合征患者血清学阳性比值比显著高于对照(OR 4.42;95%CI 2.82-6.92)。
- 乳糜泻比值比在不同性别和肠易激综合征亚型间相似。
临床怎么用
- 作者认为,不排除乳糜泻不应作出肠易激综合征的阳性诊断。
局限性
- 来自欧洲的研究数量有限,且无来自美国的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Irritable bowel syndrome (IBS) and celiac disease (CeD) are common disorders that share overlapping symptoms. In this systematic review and meta-analysis, we aimed to provide up-to-date and comprehensive estimates of the prevalence of CeD in patients with IBS. METHODS: We searched several databases through January 2025 for studies reporting the prevalence of CeD in patients with IBS. Eligible studies used Rome III or Rome IV criteria for IBS diagnosis and used serological screening with tissue transglutaminase, endomysial antibodies, or deamidated gliadin peptide, and/or confirmatory duodenal biopsies for CeD diagnosis. We used random-effects meta-analysis to estimate the pooled prevalence of seropositive and biopsy-proven CeD with 95% confidence intervals (CI). We calculated pooled odds ratios to compare the likelihood of CeD between patients with IBS and controls. RESULTS: A total of 29 studies comprising 7,209 patients with IBS were included. The pooled seroprevalence of CeD in patients with IBS was 6% (95% CI, 5%-8%), and the pooled prevalence of biopsy-proven CeD was 2% (95% CI, 2%-3%). A significant proportion of seropositive patients (15%; 95% CI, 6%-24%) did not undergo endoscopy and biopsy. Patients with IBS had significantly higher odds of a positive serology than controls (odds ratio 4.42; 95% CI, 2.82-6.92). The odds of CeD were similar across genders and IBS subtypes. There was a limited number of studies from Europe and no studies from the United States. DISCUSSION: CeD is highly prevalent in patients with IBS, according to the Rome III and Rome IV criteria. A positive diagnosis of IBS should not be made without excluding CeD.
引用
- Shiha MG, Schiepatti A, Manza F, et al. Global Prevalence of Celiac Disease in Patients With Rome III and Rome IV Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2025. PMID: 40493044. doi:10.14309/ajg.0000000000003586
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。